Ignite Creation Date:
2024-05-05 @ 12:01 PM
Last Modification Date:
2024-10-26 @ 9:18 AM
Study NCT ID:
NCT00214214
Status:
WITHDRAWN
Last Update Posted:
2015-10-08
First Post:
2005-09-13
Brief Title:
A Pilot Study to Determine the Safety of Campath-1H Anti-CD52 Antibody Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
Sponsor:
University of Wisconsin Madison
Organization:
University of Wisconsin Madison
Study Overview
Official Title:
A Pilot Study to Determine the Safety of Campath-1H Anti-CD52 Antibody Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus
Status:
WITHDRAWN
Status Verified Date:
2015-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The rationale for the study is to determine if Campath-1H can be used in patients recently diagnosed with type I DM to induce a state of immunological unresponsiveness such that subjects can safely preserve beta cell mass and eliminate or lower insulin requirements preserving excellent metabolic control
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None